NEUROFENCINE
DEAD

Serial Number

85096180

Owner

Gilad Varda

First Use Date

Jan 27, 2010

Filing Date

Jul 29, 2010

Add to watchlist:

No watchlists yet
View on USPTO

NEUROFENCINE Trademark

Serial Number: 85096180

NEUROFENCINE is a trademark filed by Gilad Varda on July 29, 2010. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Gilad Varda (6 trademarks)

Henderson, NV 89015

Entity Type: 01

Gilad Gad M (3 trademarks)

Henderson, NV 89015

Entity Type: 01

Trademark Details

Filing Date

July 29, 2010

Registration Date

Not Registered

First Use Anywhere

January 27, 2010

First Use in Commerce

January 27, 2010

Goods & Services

Animal feed additive for use as a nutritional supplement for medical purposes; Animal feed supplements; Anti-diabetic pharmaceuticals; Cardiovascular pharmaceuticals; Dietary and nutritional supplements; Dietary and nutritional supplements containing agmatine, G-agmatine; Dietary and nutritionally fortified food products adapted for medical use; Dietary beverage supplements for human consumption in liquid and dry mix form for therapeutic purposes; Dietary drink mix for use as a meal replacement; Dietary food supplements; Dietary pet supplements in the form of pet treats; Dietary supplement beverage for healthy nervous system; Dietary supplemental drinks; Dietary supplemental drinks in the nature of vitamin and mineral beverages; Dietary supplements; Dietary supplements also containing agmatine, G-agmatine; Dietary supplements for animals; Dietary supplements for human consumption; Dietary supplements for pets; Dietary supplements for pets in the nature of a powdered drink mix; Feed supplements for healthy nervous system; Food supplements; Foods for individuals with special dietary requirements necessitated by medical treatments; Health food supplements; Homeopathic pharmaceuticals for use in the treatment of nervous system damage; Homeopathic supplements; Liquid nutritional supplement; Meal replacement and dietary supplement drink mixes; Medicated supplements for foodstuffs for animals; Medicated supplements for foodstuffs for babies; Natural supplements for treating depression and anxiety; Non-medicated additives for animal feed for use as nutritional supplements; Nutraceuticals for use as a dietary supplement; Nutritional additives for medical purposes for use in foods and dietary supplements for human consumption; Nutritional additives for medical purposes used in foods and dietary supplements for human consumption; Nutritional and dietary supplements formed and packaged as bars; Nutritional supplements; Nutritional supplements in capsule form for dogs; Nutritional supplements in lotion form sold as a component of nutritional skin care products; Ocular pharmaceuticals; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological,gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; for thetreatment of inflammatory disorders; for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics,antifungal preparations and vaccines; Pharmaceutical preparations for the prevention of nervous system damage; Pharmaceutical preparations for the treatment and prevention of nervous system damage; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of nervous system damage; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for wounds; Pharmaceutical preparations for treatment and prevention of nervous system; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical products for ophthalmological use; Pharmaceutical skin lotions; Pharmaceutical solutions used in dialysis; Powdered nutritional supplement drink mix; Therapeutic pharmaceutical for the treatment of treatment and prevention of nervous system; Vitamins and dietary food supplements for animals

Filing History

ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Jun 20, 2011 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Jun 18, 2011 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 20, 2010 GNRN
NON-FINAL ACTION E-MAILED
Nov 20, 2010 GNRT
NON-FINAL ACTION WRITTEN
Nov 20, 2010 CNRT
ASSIGNED TO EXAMINER
Nov 12, 2010 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 3, 2010 NWOS
NEW APPLICATION ENTERED
Aug 2, 2010 NWAP